David Teasley, MD | |
1441 Ute Blvd, Suite 220, Park City, UT 84098-7630 | |
(435) 647-5911 | |
(435) 647-5930 |
Full Name | David Teasley |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 1441 Ute Blvd, Park City, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1942223466 | NPI | - | NPPES |
2477377 | Other | VA | CIGNA |
059947 | Other | VA | ANTHEM/HEALTHKEEPERS |
541397702 | Other | VA | AETNA |
51689 | Other | VA | OPTIMA/SENTARA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 6496301-1205 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
David Teasley, MD 1441 Ute Blvd, Suite 220, Park City, UT 84098-7630 Ph: (435) 647-5911 | David Teasley, MD 1441 Ute Blvd, Suite 220, Park City, UT 84098-7630 Ph: (435) 647-5911 |
News Archive
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
The U.S. Food and Drug Administration announced that a federal judge has approved a consent decree of permanent injunction against Butterfly Bakery Inc., a bakery based in Clifton, New Jersey, and its president, Brenda Isaac, for unlawfully distributing misbranded food products, such as muffins and snack cakes.
Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
VTT is participating in two new European projects focusing on type 2 diabetes. The projects aim at identifying new therapeutic choices and strategies for preventing the disease. Focus is on obtaining information on cellular dysfunction in diabetes and the effects of changes in lifestyle. The goal includes planning individual lifestyle instructions for people at high risk of diabetes and exploiting the results in a major European health insurance system.
Analog Devices, Inc. (ADI) today announced that Lantronix, Inc. has selected ADI's iCoupler digital isolator technology to enable its new family of wireless communication network servers.
› Verified 1 days ago